FDA Brief

Warning letters Drugs

FDA warning letter to

Varigard, LLC

High riskIssued Dec 29, 2021Posted Jan 3, 2022Center for Drug Evaluation and Research | CDER

Varigard sold hand sanitizers with unapproved COVID-19 claims as unapproved new drugs, FDA says.

What happened

FDA reviewed Varigard’s websites on August 11, 2021, and also reviewed its social media pages. It found claims that the alcohol-based hand sanitizers trap and kill COVID-19, provide two hours of protection, and kill variants and other pathogens. FDA said the products are unapproved new drugs and misbranded, with false or misleading labeling including flame-retardant claims and an FDA logo above “REGISTERED”; there was no inspection.

What FDA found

  1. FDA says the hand sanitizers are unapproved new drugs because they lack FDA approval and are not generally recognized as safe and effective for their labeled uses.

    section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  2. FDA says the products do not meet the over-the-counter (OTC) antiseptic monograph conditions for marketing without approval, including because the website presents “patented organic polymers” as active ingredients and claims two hours of efficacy.

    section 505G(a)(3) of the FD&C Act, 21 U.S.C. 355h; 1994 TFM as amended
  3. FDA says the labeling is false or misleading because it calls the alcohol-based sanitizers flame retardant or combustion resistant while they are flammable.

    section 502(a) of the FD&C Act, 21 U.S.C. 352(a); 21 CFR 201.66(c)(5)(ii)(C)
  4. FDA says labels on Varigard Hand Sanitizer Gel and Varigard Hand Sanitizer show an FDA logo above “REGISTERED,” suggesting the drugs are FDA-approved or legally marketable.

    section 502(a) of the FD&C Act, 21 U.S.C. 352(a); 21 CFR 207.77(b)
  5. FDA says the products are misbranded nonprescription drugs because they are subject to section 505G but do not comply with its marketing requirements and have no approved application.

    section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)
  6. FDA says introducing these products into interstate commerce is prohibited.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. 331(a) and (d)

What FDA wants

Within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the specific steps taken to correct the violations, prevent recurrence, and related documentation; if not completed in 48 hours, state the reason and the time needed.

Who should pay attention

  • hand sanitizer brands and retailers making COVID-19 claims
  • contract manufacturers and labelers of alcohol-based antiseptics
  • companies using FDA logos or “registered” statements on drug labels

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk